Methylnaltrexone
- Generic Name
- Methylnaltrexone
- Brand Names
- Relistor
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26NO4
- CAS Number
- 916055-93-1
- Unique Ingredient Identifier
- 0RK7M7IABE
- Background
Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008.
- Indication
Treatment of opioids induced constipation in palliative patients that are inadequately responding to laxative therapy.
- Associated Conditions
- Opioid Induced Constipation (OIC)
Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit
- Conditions
- Opioid-induced Constipation
- Interventions
- Drug: Placebo-Normal Saline
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2010-01-15
- Lead Sponsor
- St. John Health System, Michigan
- Target Recruit Count
- 80
- Registration Number
- NCT01050595
- Locations
- 🇺🇸
Providence Hospital and Medical Center, Southfield, Michigan, United States
Opioids and Esophageal Function
- Conditions
- Pharyngeal DysfunctionEsophageal Dysfunction
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2011-12-09
- Lead Sponsor
- Region Örebro County
- Target Recruit Count
- 13
- Registration Number
- NCT01012960
- Locations
- 🇸🇪
Department of Anaesthesiology, University Hospital Örebro, Örebro, Sweden
🇸🇪University Hospital Örebro, Örebro, Sweden
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
- Conditions
- NeoplasmsOpioid-Related DisordersConstipation
- Interventions
- First Posted Date
- 2009-10-29
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 12
- Registration Number
- NCT01004393
- Locations
- 🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States
Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?
- Conditions
- Colonic Inertia
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Beth Israel Medical Center
- Registration Number
- NCT00949377
Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00936884
Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects
- Conditions
- Opioid-Induced Constipation
- Interventions
- Drug: placebo
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Registration Number
- NCT00858754
- Locations
Pfizer Investigational Site
Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 156
- Registration Number
- NCT00672139
- Locations
- 🇬🇧
Salix Investigational Site, Cheltenham, Gloucestershire, United Kingdom
🇲🇽Pfizer Investigational Site, Mexico City DF, Mexico
Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
- Conditions
- Opioid-Induced Constipation
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 237
- Registration Number
- NCT00672477
- Locations
- 🇬🇧
Salix Investigational Site, Cheltenham, Gloucestershire, United Kingdom
🇲🇽Pfizer Investigational Site, Mexico City DF, Mexico
Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures
- Conditions
- Opioid-induced Constipation
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT00640146
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc, Tarrytown, New York, United States
Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT00605644
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.